Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:ENTL (ENTL) (ENTL) Stock Price, News & Analysis Add Share Share Stock Analysis Stock Analysis About (ENTL) Stock (NASDAQ:ENTL) 30 days 90 days 365 days Advanced Chart Ad Porter & CompanyVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.Including the name of the #1 company to buy. Get (ENTL) alerts:Sign Up Key Stats Today's Range$24.00▼$24.0050-Day Range$24.00▼$24.0652-Week Range$11.47▼$25.58VolumeN/AAverage Volume178,331 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewEntellus Medical, Inc. is a medical technology company. The Company is focused on delivering patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients. Its three core product lines, XprESS Multi-Sinus Dilation Systems, MiniFESS Surgical Instruments, and FocESS Imaging & Navigation, are designed to enable ear, nose and throat (ENT), physicians to perform a range of procedures in the ENT physician office and to simplify operating room-based treatment. The Company's XprESS Multi-Sinus Dilation family of products consists of its XprESS Pro device, its XprESS LoProfile device and its XprESS Ultra device. The MiniFESS family of surgical instruments includes eight devices designed to enable physicians to perform various surgical procedures. The Fiagon Image Guidance System (IGS) consists of a navigation unit, navigation sensor, software instruments and a patient localizer.Read More… Receive ENTL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for (ENTL) and its competitors with MarketBeat's FREE daily newsletter. Email Address ENTL Stock News HeadlinesHannover 96 entlässt Trainer LeitlDecember 29, 2024 | msn.comHannover 96 entlässt Trainer Leitl – Nachfolger soll noch 2024 bekannt gegeben werdenDecember 29, 2024 | msn.comWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indicates the Oracle of Omaha is quietly preparing for a historic market crash. His most reliable crash indicator - the "Buffett indicator" - just flashed red for the first time in 25 years.January 2, 2025 | Behind the Markets (Ad)Bis Ende Monat: Hilfswerk Heks entlässt rund 40 MitarbeiterNovember 14, 2024 | msn.comHilfswerk Heks entlässt bis Ende Monat rund 40 AngestellteNovember 14, 2024 | msn.com23andMe entlässt großen Teil der MitarbeitendenNovember 13, 2024 | msn.comHaiti will Regierungschef in eskalierender Sicherheitslage austauschenNovember 11, 2024 | msn.comMedien: TSG Hoffenheim entlässt Matarazzo - holt Schicker jetzt Ilzer?November 11, 2024 | msn.comSee More Headlines ENTL Stock Analysis - Frequently Asked Questions How were (ENTL)'s earnings last quarter? (ENTL) (NASDAQ:ENTL) issued its quarterly earnings data on Thursday, November, 3rd. The medical technology company reported ($0.50) earnings per share for the quarter, missing analysts' consensus estimates of ($0.37) by $0.13. The firm's quarterly revenue was up 20.9% on a year-over-year basis. When did (ENTL) IPO? (ENTL) (ENTL) raised $70 million in an initial public offering on Friday, January 30th 2015. The company issued 4,400,000 shares at a price of $15.00-$17.00 per share. BofA Merrill Lynch and Piper Jaffray served as the underwriters for the IPO and William Blair and Canaccord Genuity were co-managers. What other stocks do shareholders of (ENTL) own? Based on aggregate information from My MarketBeat watchlists, some other companies that (ENTL) investors own include Intersect ENT (XENT), Bristol-Myers Squibb (BMY), (RLYP) (RLYP), Twitter (TWTR), Altisource Asset Management (AAMC), ACADIA Pharmaceuticals (ACAD) and AcelRx Pharmaceuticals (ACRX). Company Calendar Last Earnings11/03/2016Today1/02/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorN/A Industry N/A Sub-IndustryN/A Current SymbolNASDAQ:ENTL CUSIPN/A CIK1374128 Webwww.entellusmedical.com Phone+1-763-4631595FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A A Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free Report This page (NASDAQ:ENTL) was last updated on 1/2/2025 by MarketBeat.com Staff From Our Partners3 CENT Crypto to Explode December 16th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe crypto bull market is here, and the stakes couldn’t be higher. The next 3-6 months? They’re the most ex...Crypto Swap Profits | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | SponsoredMissed Nvidia? Buy Elon Musk’s “Silent Partner”In February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my f...Brownstone Research | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredFirst JFK… next Elon?Today, I have another controversial prediction. One which I will take no pleasure in seeing come true. ...Porter & Company | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding (ENTL) Please log in to your account or sign up in order to add this asset to your watchlist. Share (ENTL) With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.